Drug Evaluation Committee Implementation and Management, etc. of Clinical trials under the spread of the novel coronavirus (COVID-19)
In light of the novel coronavirus (COVID-19) outbreak in 2020, we understand that each company is taking appropriate measures.
Member companies of the JPMA must continue to conduct clinical trials in an appropriate manner while implementing measures to prevent the spread of infection.
The Clinical Evaluation Subcommittee, in collaboration with the Japan SMO Association and the Japan CRO Association, has issued “ Implementation and Management, etc. of Clinical trials under the spread of the novel coronavirus (COVID-19)” in the form of a joint statement. We kindly ask that you share this widely with all relevant parties.
(Clinical Evaluation Subcommittee)